Update on emerging infections: News from the centers for disease control and prevention: Staphylococcus aureus resistant to vancomycin - United States, 2002

Annals of Emergency Medicine

Volumn 41, Issue 1, 2003, Pages 148-151

  Moran, Gregory J ^a,b   Mount, Jason ^a   Talan, David A ^b   Pinner, Robert ^c  

^a OLIVE VIEW UCLA MEDICAL CENTER   (United States)

^b UCLA MEDICAL CENTER   (United States)

^c CENTERS FOR DISEASE CONTROL AND PREVENTION   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEPHALOSPORIN DERIVATIVE; CHLORAMPHENICOL; CLINDAMYCIN; COTRIMOXAZOLE; DALFOPRISTIN PLUS QUINUPRISTIN; DICLOXACILLIN; GENTAMICIN; LINEZOLID; METICILLIN; MINOCYCLINE; NAFCILLIN; OXACILLIN; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; TETRACYCLINE; TETRACYCLINE DERIVATIVE; VANCOMYCIN;

ANTIBIOTIC PROPHYLAXIS; ANTIBIOTIC RESISTANCE; ANTIBIOTIC THERAPY; BACTERIAL ENDOCARDITIS; DRUG CHOICE; HUMAN; INFECTION CONTROL; METHICILLIN RESISTANT STAPHYLOCOCCUS AUREUS; MINIMUM INHIBITORY CONCENTRATION; NOTE; PRACTICE GUIDELINE; PRIORITY JOURNAL; SOFT TISSUE INFECTION; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION;

EID: 0037229197     PISSN: 01960644     EISSN: None     Source Type: Journal    
DOI: 10.1067/mem.2003.26     Document Type: Article

References (15)

1. Centers for Disease Control and Prevention. National Nosocomial Infections Surveillance report, data summary from October 1986 - April 1996, issued May 1996. Am J Infect Control. 1996;24:380-388.
2. Waldvogel FA. Staphylococcus aureus (including toxic shock syndrome). In: Mandell GL, Bennett JE, Dolin R, eds. Mandell, Douglas and Bennett's Principles and Practice of Infectious Diseases. 4th ed. New York, NY: Churchill Livingstone; 1995:1754-1777.
3. Hiramatsu K, Hanaki H, Ino T, et al. Methicillin-resistant Staphylococcus aureus clinical strain with reduced vancomycin susceptibility. J Antimicrob Chemother. 1997;40:135-136.
4. National Committee for Clinical Laboratory Standards. Methods for Dilution Antimicrobial Susceptibility Tests for Bacteria That Grow Aerobically 5th ed. Approved standard, M7-A5. Wayne, PA: National Committee for Clinical Laboratory Standards; 2000.
5. Smith TL, Pearson ML, Wilcox KR, et al. Emergence of vancomycin resistance in Staphylococcus aureus. N Engl J Med 1999;340:493-501
6. Fridkin SK. Vancomycin-intermediate and -resistant Staphylococcus aureus: what the infectious disease specialist needs to know. Clin Infect Dis. 2001;32:108-115.
7. Centers for Disease Control and Prevention. Recommendations for preventing transmission of infections among chronic hemodialysis patients. MMWR Morb Mortal Wkly Rep. 2001;50(RR-5).
8. Centers for Disease Control and Prevention. Interim guidelines for prevention and control of staphylococcal infections associated with reduced susceptibility to vancomycin. MMWR Morb Mortal Wkly Rep. 1997;46:626-628, 635.
9. Woodford N. Epidemiology of the genetic elements responsible for acquired glycopeptide resistance in enterococci. Microb Drug Resist 2001;7:229-236.
10. Noble WC, Virani Z, Cree RG. Co-transfer of vancomycin and other resistance genes from Enterococcus faecalis NCTC 12201 to Staphylococcus aureus. FEMS Microbiol Lett. 1992;93:195-198.
11. Chambers HF. The changing epidemiology of Staphylococcus aureus? Emerg Infect Dis. 2001;7:178-182.
12. Centers for Disease Control and Prevention. Four pediatric deaths from community-acquired methicillin-resistant Staphylococcus aureus - Minnesota and North Dakota, 1997-1999. MMWR Morb Mortal Wkly Rep 1999;48:707-710.
13. Garner JS, Hospital Infection Control Practices Advisory Committee. Guideline for isolation precautions in hospitals. Infect Control Hosp Epidemiol. 1996;17:53-80.
14. Moran GJ. Commentars: reduced susceptibility of Staphylococcus aureus to vancomycin - United States, 1997. Ann Emerg Med. 1998;31:121-123.
15. Dajani AS, Taubert KA, Wilson W, et al. Prevention of bacterial endocarditis: recommendations by the American Heart Association. JAMA. 1997;277:1794-1801.